INJECTIVE — The history of the project
Disclaimer: The information contained in this article and the resources available is not intended as, and shall not be understood or construed as, financial advice. Nothing available on this page should be understood as a recommendation to buy something.
📚 This article is a part of the Injective’s HUB of knowledge.
If you want to acquire more knowledge about the project and its whole ecosystem then follow the main article. You can find there the basic information and references to numerous specific articles.
Stay up to date and explore the Injective world!
📚 I. The history of Injective.
Injective was founded in 2018 by a team of experienced entrepreneurs and engineers with the aim of creating a truly decentralized trading platform that is fast, secure, and accessible to everyone. The founding team, led by Eric Chen and Albert Chon, saw the limitations of existing trading platforms and recognized the need for a truly decentralized and scalable solution.
The team started working on the project in late 2018 and released the initial whitepaper in January 2019. The project quickly gained attention in the blockchain community, and in April 2019, Injective raised $2.6 million in a seed funding round led by Pantera Capital and Hashed. The funding allowed the team to expand its development efforts and accelerate the launch of the platform.
Over the next two years, the Injective team worked tirelessly on building the platform, which involved developing a unique layer-1 protocol that could support decentralized trading of various assets. The team also focused on creating a user-friendly interface and implementing various security measures to ensure that the platform is secure and resistant to attacks.
In November 2020, Injective launched its Testnet, which allowed users to test the platform and provide feedback. The Testnet received positive feedback from the community, and the team continued to work on improving the platform based on the feedback received.
On November 8th, 2021, Injective launched its Mainnet, marking a major milestone for the project. The Mainnet launch was highly anticipated by the community, and it attracted a lot of attention from investors and traders. The launch was successful, and the platform is now live, allowing users to trade various assets in a fast, secure, and fully decentralized manner.
Overall, Injective has come a long way since its inception, and the project has the potential to revolutionize the way people trade and interact with digital assets. The project’s unique features, such as its MEV-resistant and Frontrunning-Bounded Auctions (FBA) mechanism, as well as its out-of-the-box modules, make it a truly special and innovative project in the blockchain space.
📌 II. Injective founders.
I. Eric Chen
Eric Chen is a blockchain entrepreneur and the co-founder of Injective, a decentralized exchange platform that allows users to trade various assets in a fully decentralized manner. Chen has been involved in the blockchain industry since its early days and has played a key role in driving the adoption of decentralized technology. He is highly respected in the blockchain community for his technical expertise and visionary approach to creating innovative solutions.
Prior to co-founding Injective, Chen worked as a software engineer at Google, where he gained valuable experience in developing large-scale distributed systems. He also co-founded the blockchain infrastructure provider company, Anchor, which focuses on providing solutions to help developers build and deploy decentralized applications.
Chen’s passion for blockchain technology has led him to speak at numerous industry events, including the Global Blockchain Summit and the Asia Blockchain Summit. He is committed to creating decentralized solutions that empower users and has been recognized for his contributions to the blockchain space, being named in Forbes’ 30 under 30 in Asia list in 2021. As a co-founder of Injective, Chen is dedicated to creating a decentralized platform that offers users fast, secure, and fully decentralized trading.
II. Albert Chon
Albert Chon is a co-founder of Injective, a decentralized exchange platform that enables users to trade any asset across various blockchains without any restrictions. He is also the current Chief Technical Officer (CTO) of the project.
Chon graduated from Carnegie Mellon University with a Bachelor of Science degree in Electrical and Computer Engineering. Prior to co-founding Injective, he worked as a Software Engineer at Google, where he focused on developing large-scale distributed systems.
Chon’s expertise in software engineering and distributed systems has been crucial in the development of Injective. He is responsible for overseeing the technical aspects of the platform, including its architecture, security, and performance. His contributions have helped the project to achieve its mission of creating a truly decentralized and permissionless trading experience for users worldwide.
📚 III. How Injective becomes the first Binance Labs incubation project?
In 2018, Injective was selected as one of eight winners for incubation with Binance Labs, a venture arm of Binance, with the goal of addressing the poor liquidity, high latency, and inefficiencies seen at most decentralized exchanges. Since then, Binance has supported Injective’s vision of building a product that solves these major issues, including poor UX, slow speeds, centralization, and high fees.
In October 2020, Injective officially became the next project to launch on Binance Launchpad, Binance’s selective public sale platform. This launch marked the 17th launch on Binance Launchpad since its inception in late 2017, and it was widely popular for its fair selection process that helps distribute tokens to thousands of participants.
Being incubated by Binance Labs and launching on Binance Launchpad made Injective the first Binance Labs incubated project to debut on Binance Launchpad. This was a significant achievement for the project, as Binance is one of the most reputable and influential cryptocurrency exchanges in the world, with a vast user base and market reach.
Injective’s founder, Eric Chen, expressed his excitement about the launch, stating that Injective helps to alleviate all of the problems of traditional exchanges while offering the best trading experience for both institutions and individuals globally. Since the raise, Injective has been working diligently towards a mainnet launch later in 2020 and has announced partnerships with top blockchain companies such as Elrond, Ramp DeFi, Findora, and Frontier.
